Source:http://linkedlifedata.com/resource/pubmed/id/19012301
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2009-1-20
|
pubmed:abstractText |
We report a Becker muscular dystrophy (BMD) family with one 5-year-old affected patient and a 69-year-old asymptomatic grandfather. Dystrophin gene multiplex polymerase chain reaction and multiplex ligation-dependant probe amplification analysis showed that both males carried an in-frame deletion of exons 45-55. Segregation analysis revealed two additional asymptomatic boys in this family. Our finding supports previous predictions that exons 45-55 are the optimal multiexon skipping target in antisense gene therapy to transform the severe Duchenne muscular dystrophy into the milder BMD, or even asymptomatic, phenotype.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0148-639X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
239-43
|
pubmed:meshHeading |
pubmed-meshheading:19012301-Aged,
pubmed-meshheading:19012301-Child, Preschool,
pubmed-meshheading:19012301-Dystrophin,
pubmed-meshheading:19012301-Exons,
pubmed-meshheading:19012301-Family Health,
pubmed-meshheading:19012301-Female,
pubmed-meshheading:19012301-Gene Dosage,
pubmed-meshheading:19012301-Humans,
pubmed-meshheading:19012301-Male,
pubmed-meshheading:19012301-Muscular Dystrophy, Duchenne,
pubmed-meshheading:19012301-Sequence Analysis,
pubmed-meshheading:19012301-Sequence Deletion
|
pubmed:year |
2009
|
pubmed:articleTitle |
Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion.
|
pubmed:affiliation |
Genetics Division, Clinical Hospital "José de San Martín," University of Buenos Aires, 2250 Paraguay, 1120 Buenos Aires, Argentina. vferreiro@ffyb.uba.ar
|
pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|